On October 19, 2026 Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, reported that six studies involving its genomic tests will be presented at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2026, taking place October 23-27 in Madrid, Spain. The presentations span treatment selection and risk assessment in prostate and bladder cancer, as well as a late-breaking health economic analysis from the Phase III landmark OPTIMA breast cancer trial.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A prostate cancer oral presentation will provide the first evidence that the Decipher Prostate test predicts benefit from adding abiraterone to androgen deprivation therapy for patients with clinically very high-risk, nonmetastatic disease. The findings extend Decipher’s predictive evidence into another treatment setting and build on its established role in prostate cancer risk stratification and treatment benefit. A separate oral presentation will report a within-trial economic analysis of Prosigna-guided chemotherapy decisions in OPTIMA.

"The research being presented at ESMO (Free ESMO Whitepaper) reflects how understanding a tumor’s biology can inform decisions across cancer care," said Phillip Febbo, M.D., Veracyte’s chief scientific and medical officer. "The Decipher Prostate study will provide the first evidence that the test predicts benefit from adding abiraterone to treatment for patients with clinically very high-risk disease. Alongside the OPTIMA economic analysis and new bladder cancer research, these studies address questions that matter to patients and clinicians."

Veracyte-related presentations at ESMO (Free ESMO Whitepaper) 2026

Oral presentations:

Title: Transcriptome classifier risk stratification and intensification with androgen receptor pathway inhibitors (ARPI) for clinically very high-risk prostate cancer (PCa)

Presenter: Sarah Howlett, M.B.B.S., Clinical Research Fellow, Research Department of Oncology, University College London
Abstract #: 2045O
Date and time: Saturday, October 24, 10:15–11:45 a.m. CEST
Location: Barcelona Auditorium, Hall 9
Late-breaking oral presentation:

Title: Within-trial economic analysis of chemotherapy for high-risk early breast cancer informed by a 50-gene assay: 2-year results from the OPTIMA randomised trial

Presenter: Peter Hall, M.B.Ch.B., Ph.D., Professor of Medical Oncology (Cancer Informatics), University of Edinburgh
Abstract #: LBA86
Date and time: Sunday, October 25, 10:15 a.m. – 11:45am CET
Location: Seville Auditorium – NCC
Poster presentations

Title: Age at Diagnosis as an Independent Prognostic Factor in Urothelial Carcinoma: Impact on Survival and Immune Microenvironment Within Molecular Subtypes

Presenter: Michela Piacentini, M.D., Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan
Abstract #: 4746P
Date and time: Friday, October 23, 3:15–4:00 p.m. CEST
Title: Prognostic Value of the Decipher Prostate Genomic Classifier (GC) and Neuroendocrine (NE) Gene Expression Signatures in Real-World De Novo Metastatic (M1) Prostate Cancer

Presenter: Alice Bernard-Tessier, M.D., medical oncologist, Gustave Roussy; Research Fellow, Dana-Farber Cancer Institute
Abstract #: 4465P
Date and time: Friday, October 23, 3:15–4:00 p.m. CEST
Title: A Scar-like Transcriptomic Classifier Confirms Favorable Outcomes in Patients with Residual Bladder Cancer (BC) after Perioperative Chemo-immunotherapy

Presenter: Chiara Mercinelli, M.D., Medical Oncologist, IRCCS San Raffaele Hospital and Scientific Institute, Milan
Abstract #: 4521eP
Date and time: electronic poster
Title: Evaluating the prognostic utility of a genomic classifier (GC) in an Asian real-world cohort of localized prostate cancer (PCa)

Presenter: Melvin Lee Kiang Chua, M.B.B.S., Ph.D., Head and Senior Consultant, National Cancer Centre Singapore; Professor, Duke-NUS Medical School
Abstract #: 2061eP
Date and time: electronic poster

(Press release, Veracyte, OCT 19, 2026, View Source [SID1234673570])